'BioBoom'
A 2018 CommonHealth series on why the world's leading biomedical ecosystem is here, and what it means for the area.
Next Era For Biotech: Designer Cells To Attack Diseases
A biotech CEO argues that the biggest news in the sector is not the creation of cures for specific diseases but rather of whole new types of treatments.
Could The 'BioBoom' Go Bust? How One MIT Professor Sees It
The hope and promise of lifesaving medical treatments fuel biotech investor exuberance to the tune of billions of dollars per year in Massachusetts. MIT's Andrew Lo breaks down how a...
Next Chapter For Biotech? Many Say 'Convergence' With Data Science
Artificial intelligence, big data analytics and deep learning are converging on health care in a big way, experts insist.
Genetic Diseases Steal Too Many Kids' Futures. It Doesn't Have To Be This Way
The biotech industry needs to invest more in developing therapies for childhood diseases, ideally ones that can be given before symptoms arise, writes Geoff McDonough.
Number Of Women Leaders At Biotech Companies Lags — But Is Improving
Two leaders in biotech -- both women -- discuss how women in management benefit biotech companies, and what's being done to bring more women into executive office suites and board...
Advertisement
Affording Miracles: As Biotech Victories In Gene Therapy Excite, Costs Spur Quest For New Ways To Pay
The first-approved gene therapy costs an eye-popping $142,000 per drop, helping to spur the quest to find better ways of pricing and paying for these miraculous new treatments.
One Of Biotech's Biggest Investors Says The Industry Must Be 'Unreasonable'
Noubar Afeyan is one of biotech's most prolific investors.
How Is The BioBoom Changing The Community — And Culture — Of Cambridge?
We speak with Cambridge residents about how the biotech explosion is affecting the city, from swelling rents to -- arguably -- the further corporatization of Harvard Square.
This Biotech Unicorn Hopes To Revolutionize Drug Making, But It Has Its Skeptics
Investors think Moderna Therapeutics holds a lot of promise -- a new technology that could revolutionize thousands of medicines.
Tribes Of Kendall Square: How To Parse Who's Who In Hotbed Of Biotech
The dense Boston-area cluster of biotech has a culture and cast of characters all its own -- academics, entrepreneurs, venture capitalists -- much as Silicon Valley does.
Women And People Of Color Are Underrepresented In Mass. BioTech. That Has To Change
It's time for the life sciences industry to expand access and opportunity to more women, people of color and people at all socioeconomic levels, writes David Lucchino, the chairman of...
How Kendall Square Became The Epicenter Of The Biotech World
We look at the history of the biotech industry in Boston.
Biotech Startups: Dreams, Risk, Failure And — Sometimes — Success
Hundreds of startups help power the Boston area's biotech boom, but it's widely accepted that failures vastly exceed successes.
Boston's Vertex Has Taken A Roller Coaster Ride To Profitability
Along the way Vertex got a boost from a unique funding source and, as a result, developed an unusual business model.
Mass. Life Sciences Center Anticipates $500 Million State Investment
The state Legislature is expected to pass a measure that would invest another $500 million in life science over the next five years.
Primer: How To Speak Basic Biotech, From 'Transformative' To 'Valley Of Death'
The Boston area's booming biotech cluster is a little like a country with its own culture. And cultures tend to have languages.
The Biotech Boom: By The Numbers
There are well over 250 biotech companies in Cambridge, according to one tally, with a significant portion in and around Kendall Square.
In The Heart Of Biotech, Leaders Explain The Boston Area’s 'BioBoom'
As biology continues to revolutionize medicine, biotech is becoming a defining industry of this region.